Drug
Ruxolitinib 1.5% Cream
Ruxolitinib 1.5% Cream is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
1(20%)
Results Posted
200%(4 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_2
5
100%
Phase Distribution
0
Early Stage
5
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
5(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(2)
Terminated(2)
Detailed Status
Terminated2
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 25 (100.0%)
Trials by Status
terminated240%
completed240%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
terminatedphase_2
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
NCT04414514
completedphase_2
Ruxolitinib in Seborrheic Dermatitis
NCT05787860
recruitingphase_2
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
NCT06261021
completedphase_2
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
NCT05247489
terminatedphase_2
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
NCT03395340
Clinical Trials (5)
Showing 5 of 5 trials
NCT04414514Phase 2
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
NCT05787860Phase 2
Ruxolitinib in Seborrheic Dermatitis
NCT06261021Phase 2
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
NCT05247489Phase 2
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
NCT03395340Phase 2
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5